You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

BOSENTAN - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for bosentan and what is the scope of freedom to operate?

Bosentan is the generic ingredient in two branded drugs marketed by Actelion, Alembic, Alvogen Pine Brook, Amneal Pharms Co, Chartwell Molecular, Endo Operations, Hikma, Mylan, Natco Pharma Ltd, Sun Pharm, Watson Labs Inc, and Zydus Pharms, and is included in thirteen NDAs. There are two patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Bosentan has twenty-eight patent family members in twenty-three countries.

There are nineteen drug master file entries for bosentan. Six suppliers are listed for this compound. There are three tentative approvals for this compound.

Drug Prices for BOSENTAN

See drug prices for BOSENTAN

Recent Clinical Trials for BOSENTAN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
CTI BioPharmaPhase 1
PPDPhase 1
Jean-Pierre RoutyN/A

See all BOSENTAN clinical trials

Generic filers with tentative approvals for BOSENTAN
Applicant Application No. Strength Dosage Form
⤷  Sign Up⤷  Sign Up125MGTABLET;ORAL
⤷  Sign Up⤷  Sign Up62.5MGTABLET;ORAL
⤷  Sign Up⤷  Sign Up32MGTABLET, FOR SUSPENSION;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Paragraph IV (Patent) Challenges for BOSENTAN
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
TRACLEER for Oral Suspension bosentan 32 mg 209279 1 2019-02-08

US Patents and Regulatory Information for BOSENTAN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Chartwell Molecular BOSENTAN bosentan TABLET;ORAL 210342-001 Jan 3, 2020 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Amneal Pharms Co BOSENTAN bosentan TABLET;ORAL 209742-002 Apr 26, 2019 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Alvogen Pine Brook BOSENTAN bosentan TABLET;ORAL 206002-001 Apr 26, 2019 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Amneal Pharms Co BOSENTAN bosentan TABLET;ORAL 209742-001 Apr 26, 2019 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Actelion TRACLEER bosentan TABLET, FOR SUSPENSION;ORAL 209279-001 Sep 5, 2017 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Natco Pharma Ltd BOSENTAN bosentan TABLET;ORAL 206987-002 Apr 26, 2019 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Watson Labs Inc BOSENTAN bosentan TABLET;ORAL 207110-001 Apr 26, 2019 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for BOSENTAN

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Janssen-Cilag International N.V.   Tracleer bosentan EMEA/H/C/000401
Treatment of pulmonary arterial hypertension (PAH) to improve exercise capacity and symptoms in patients with WHO functional class III.Efficacy has been shown in:, , , Primary (idiopathic and familial) PAH;, PAH secondary to scleroderma without significant interstitial pulmonary disease;, PAH associated with congenital systemic-to-pulmonary shunts and Eisenmenger's physiology., , , Some improvements have also been shown in patients with PAH WHO functional class II., , Tracleer is also indicated to reduce the number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcer disease.,
Authorised no no no 2002-05-14
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for BOSENTAN

Country Patent Number Title Estimated Expiration
China 101175484 Dispersible bosertan tablet ⤷  Sign Up
Australia 2006248593 Dispersible bosertan tablet ⤷  Sign Up
Japan 2008540512 ⤷  Sign Up
South Korea 20100093105 DISPERSIBLE TABLET ⤷  Sign Up
New Zealand 564167 Dispersible tablet comprising 4-tert-butyl-N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(pyrimidin-2-yl)-pyrimidin-4-yl]-benzenesulfonamide (bosutan) ⤷  Sign Up
Portugal 1883397 ⤷  Sign Up
South Korea 20080014002 DISPERSIBLE TABLET ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for BOSENTAN

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0526708 C300097 Netherlands ⤷  Sign Up PRODUCT NAME: BOSENTAN, DESGEWENST IN DE VORM VAN EEN ZOUT OF EEN HYDRAAT OF IN DE VORM VAN EEN ESTER VAN DE HYDROXYLGROEP VAN DE 2-HYDROXYETHOXY REST MET EEN ZUUR MET DE FORMULE R5-OH, WAARIN R5 EEN C1-7-ALKANOYL, BENZOYL, OF HETEROCYCLYCARBONYL VOORSTELT; NATL. REGISTRATION NO/DATE: U/1/02/220/001 - 005 20020515; FIRST REGISTRATION: CH IKS 58841 01 - 02 20020228
0526708 0290017-3 Sweden ⤷  Sign Up PRODUCT NAME: BOSENTAN ELLER ETT SALT DAERAV; NAT. REGISTZRATION NO/DATE: EU/1/02/220/001 20020515; FIRST REGISTRATION: CH 55841 01 20020228
0526708 02C0042 France ⤷  Sign Up PRODUCT NAME: BOSENTAN MONOHYDRATE; NAT. REGISTRATION NO/DATE: EU/1/02/220/001 20020515; FIRST REGISTRATION: LI - 55841 20020228
0526708 SPC/GB02/030 United Kingdom ⤷  Sign Up PRODUCT NAME: BOSENTAN 4-(1,1-DIMETHYLETHYL)-N-(6-(2-HYDROXYETHOXY)-5-(2-METHOXYPHENOXY)-2(PYRIMIDIN-2-YL)PYRIMIDIN-4-YL)BENZENESULFONAMIDE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.